Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChristina PohRARanjana H. AdvaniUAUmut Aypar

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates gene rearrangements influence survival in ALK-negative ALCL treated with BV-CHP.

Key Points

  • To determine the impact of DUSP22 and TP63 rearrangements on outcomes in ALK-negative sALCL treated with frontline BV-CHP.
  • Multicenter retrospective analysis of ALK-negative sALCL patients treated with BV-based chemotherapy.
  • FISH testing for gene rearrangements and IHC for tumor markers was performed.
  • Kaplan-Meier methods were used to analyze progression-free survival (PFS) and overall survival (OS).
  • DUSP22 rearrangement was present in 28% and TP63 in 7% of cases.
  • The median PFS was 67 months and median OS was 94 months.
  • Higher IPI scores and advanced stage were associated with worse PFS.

Cite This Study

Poh et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2d4https://doi.org/10.1182/blood-2025-5410
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis2025
  2. 2Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party2025
  3. 3Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study.2024 · 7 citations
  4. 4Multi‐Institutional Study of <scp>ALK</scp>‐Positive Large B‐Cell Lymphoma: Outcomes in the Era of <scp>ALK</scp> Inhibitors and Biologically Informed Therapies2025 · 3 citations
  5. 5Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study2025